Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Effective in-vitro inactivation of SARS-CoV-2 by commercially available mouthwashes

Katherine Davies, Hubert Buczkowski, Stephen R Welch, Nicole Green, Damian Mawer, Neil Woodford, Allen DG Roberts, Peter J Nixon, David W Seymour, Marian J Killip
doi: https://doi.org/10.1101/2020.12.02.408047
Katherine Davies
aHigh Containment Microbiology, National Infection Service, Public Health England, 61 Colindale Avenue, Colindale, London, NW9 5EQ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hubert Buczkowski
aHigh Containment Microbiology, National Infection Service, Public Health England, 61 Colindale Avenue, Colindale, London, NW9 5EQ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen R Welch
aHigh Containment Microbiology, National Infection Service, Public Health England, 61 Colindale Avenue, Colindale, London, NW9 5EQ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicole Green
aHigh Containment Microbiology, National Infection Service, Public Health England, 61 Colindale Avenue, Colindale, London, NW9 5EQ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Damian Mawer
bYork Hospitals NHS Foundation Trust, Wigginton Road, York, YO31 8HE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neil Woodford
cNational Infection Service, Public Health England, 61 Colindale Avenue, Colindale, London, NW9 5EQ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allen DG Roberts
aHigh Containment Microbiology, National Infection Service, Public Health England, 61 Colindale Avenue, Colindale, London, NW9 5EQ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter J Nixon
bYork Hospitals NHS Foundation Trust, Wigginton Road, York, YO31 8HE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David W Seymour
bYork Hospitals NHS Foundation Trust, Wigginton Road, York, YO31 8HE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marian J Killip
aHigh Containment Microbiology, National Infection Service, Public Health England, 61 Colindale Avenue, Colindale, London, NW9 5EQ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Marian.Killip@phe.gov.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

ABSTRACT

Infectious SARS-CoV-2 can be recovered from the oral cavities and saliva of COVID-19 patients with potential implications for disease transmission. Reducing viral load in patient saliva using antiviral mouthwashes may therefore have a role as a control measure in limiting virus spread, particularly in dental settings. Here, the efficacy of SARS-CoV-2 inactivation by seven commercially available mouthwashes with a range of active ingredients were evaluated in vitro. We demonstrate ≥4.1 to ≥5.5 log10 reduction in SARS-CoV-2 titre following a one minute treatment with commercially available mouthwashes containing 0.01-0.02% stabilised hypochlorous acid or 0.58% povidone iodine, and non-specialist mouthwashes with both alcohol-based and alcohol-free formulations designed for home use. In contrast, products containing 1.5% hydrogen peroxide or 0.2% chlorhexidine gluconate were ineffective against SARS-CoV-2 in these tests. This study contributes to the growing body of evidence surrounding virucidal efficacy of mouthwashes/oral rinses against SARS-CoV-2, and has important applications in reducing risk associated with aerosol generating procedures in dentistry and potentially for infection control more widely.

Competing Interest Statement

The authors have declared no competing interest.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 02, 2020.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Effective in-vitro inactivation of SARS-CoV-2 by commercially available mouthwashes
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Effective in-vitro inactivation of SARS-CoV-2 by commercially available mouthwashes
Katherine Davies, Hubert Buczkowski, Stephen R Welch, Nicole Green, Damian Mawer, Neil Woodford, Allen DG Roberts, Peter J Nixon, David W Seymour, Marian J Killip
bioRxiv 2020.12.02.408047; doi: https://doi.org/10.1101/2020.12.02.408047
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Effective in-vitro inactivation of SARS-CoV-2 by commercially available mouthwashes
Katherine Davies, Hubert Buczkowski, Stephen R Welch, Nicole Green, Damian Mawer, Neil Woodford, Allen DG Roberts, Peter J Nixon, David W Seymour, Marian J Killip
bioRxiv 2020.12.02.408047; doi: https://doi.org/10.1101/2020.12.02.408047

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Microbiology
Subject Areas
All Articles
  • Animal Behavior and Cognition (3698)
  • Biochemistry (7809)
  • Bioengineering (5689)
  • Bioinformatics (21330)
  • Biophysics (10595)
  • Cancer Biology (8199)
  • Cell Biology (11961)
  • Clinical Trials (138)
  • Developmental Biology (6777)
  • Ecology (10419)
  • Epidemiology (2065)
  • Evolutionary Biology (13900)
  • Genetics (9726)
  • Genomics (13094)
  • Immunology (8164)
  • Microbiology (20058)
  • Molecular Biology (7871)
  • Neuroscience (43147)
  • Paleontology (321)
  • Pathology (1280)
  • Pharmacology and Toxicology (2264)
  • Physiology (3362)
  • Plant Biology (7246)
  • Scientific Communication and Education (1315)
  • Synthetic Biology (2010)
  • Systems Biology (5547)
  • Zoology (1132)